Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD to improve pharmacovigilance framework
A new reporting tool is expected to be released in 2026.
Interim measures follow concerns about adverse event reporting processes.

The Veterinary Medicines Directorate (VMD) has shared new plans to improve its veterinary medicine safety monitoring process.

It has also announced a number of interim measures, after receiving concerns about changes to adverse event reporting processes.

As part of its measures to improve pharmacovigilance, the regulatory authority has committed to the development of an enhanced online reporting tool. The system, which will integrate existing processes, is expected to be released in 2026.

The VMD is working to develop two additional systems to improve its assessments.

The first process is a signal management system. This will integrate safety signals, as well as sourcing related data from the VMD’s periodic statistical analysis and searches; MAH reports; and APHA alerts.

It is also developing its database mining, data comparison and automated incidence calculations.

In the meantime, it says it has maintained reporting routes to ensure adverse events continue to be reported. If Marketing Authorisation Holder (MAH) identification is challenging, or the report is of an unauthorised or human medicine, veterinary professionals are urged to contact the VMD’s pharmacovigilance team directly.

Recent regulatory updates, made to the Veterinary Medicines Regulations in 2024, are also said to have strengthened the VMD’s reporting systems. It now receives serious and non-serious reports of adverse events within 30 days of the MAH being notified.

The VMD says this improves data quality, reduces follow-up enquiries and enables more comprehensive initial reporting.

Amidst these changes, the VMD has encouraged veterinary professionals to continue submitting detailed reports for authorised Veterinary Medicinal Products through MAHs. Meanwhile, concerns about human medicines and unauthorised medicines should be sent directly to adverse.events@vmd.gov.uk to request a reporting form.

The regulatory authority say it has reviewed its guidance to provide clarity on the available reporting routes, and will continue to provide regular progress updates on the development of the new systems.

Giles Paiba, head of pharmacovigilance, said: “We understand stakeholder concerns about reporting accessibility and are committed to maintaining multiple reporting routes,

“These interim measures ensure comprehensive adverse event reporting whilst we develop improved long-term solutions.”

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.